Efficacy of ravuconazole in a murine model of vaginitis by Candida albicans

Achkar, 2010, Candida infections of the genitourinary tract, Clin Microbiol Rev, 23, 253, 10.1128/CMR.00076-09 American Society for Microbiology, 2007, A model of Recurrent Vaginal Candidiasis (Session 189, M-1833) Arikan, 2002, Ravuconazole Eisai/Bristol.Myers Squibb, Curr Opin Investig Drugs, 3, 555 Barry, 2000, Quality control limits for broth microdilution susceptibility test of ten antifungal agents, J Clin Microbiol, 38, 3457, 10.1128/JCM.38.9.3457-3459.2000 Calderon, 2003, Genetic susceptibility to vaginal candidiasis, Med Mycol, 41, 143, 10.1080/mmy.41.2.143.147 Clemons, 2002, Efficacy of ravuconazole in treatment of systemic murine histoplasmosis, Antimicrob Agents Chemother, 46, 922, 10.1128/AAC.46.3.922-924.2002 Clemons, 2001, Efficacy of ravuconazole intreatment of mucosal candidosis in SCID mice, Antimicrob Agents Chemother, 45, 3433, 10.1128/AAC.45.12.3433-3436.2001 Cuenca-Estrella, 2004, In vitro activities of ravuconazole and four other antifungal agents against fluconazole-resistant or susceptible clinical yeast isolates, Antimicrob Agents Chemother, 48, 3107, 10.1128/AAC.48.8.3107-3111.2004 Diekema, 2003, Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, andamphotericin B against 448 recent clinical isolates of filamentous fungi, J Clin Microbiol, 41, 3623, 10.1128/JCM.41.8.3623-3626.2003 Drogari-Apiranthitou, 2012, In vitro antifungal susceptibility of filamentous fungi causing rare infections: synergy testing of amphotericin B, posaconazole and anidulafungin in pairs, J Antimicrob Chemother, 67, 1937, 10.1093/jac/dks137 Edén, 1982, Inhibition of experimental ascending urinary tract infection by an epithelial cell surface receptor analogue, Nature, 298, 560, 10.1038/298560a0 Ernst, 2001, Investigational antifungal agents, Pharmacotherapy, 21, 165S, 10.1592/phco.21.12.165S.34509 Gonzalez, 2005, In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi, Med Mycol, 43, 281, 10.1080/13693780500088416 González, 2009, Therapeutic efficacy of voriconazole against a fluconazole-resistant Candida albicans isolate in a vaginal model, J Antimicrob Chemother, 64, 571, 10.1093/jac/dkp228 González, 2009, Efficacy of albaconazole against Candida albicans in a vaginitis model, Antimicrob Agents Chemother, 53, 4540, 10.1128/AAC.00565-09 González, 2007, Therapeutic efficacy of posaconazole against isolates of Candida albicans with different susceptibilities to fluconazole in a vaginal model, Med Mycol, 45, 221, 10.1080/13693780601164298 Hoffman, 2000, Novel triazole antifungal agents, Expert Opin Investig Drugs, 9, 593, 10.1517/13543784.9.3.593 Kirkpatrick, 2002, Efficacy of ravuconazole (BMS-207147) in a guinea pig model of disseminated aspergillosis, J Antimicrob Chemother, 49, 353, 10.1093/jac/49.2.353 Mdodo, 2011, Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates from AIDS patients in Kenya, Mycoses, 54, e438, 10.1111/j.1439-0507.2010.01946.x Messer, 2006, International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2003), J Clin Microbiol, 44, 1782, 10.1128/JCM.44.5.1782-1787.2006 Moore, 2000, In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B, Antimicrob Agents Chemother, 44, 441, 10.1128/AAC.44.2.441-443.2000 National Committee for Clinical Laboratory Standards, 2008, Reference method for broth dilution antifungal susceptibility testing of yeasts Paphitou, 2002, In vitro antifungal susceptibilities of Trichosporon species, Antimicrob Agents Chemother, 46, 1144, 10.1128/AAC.46.4.1144-1146.2002 2007 Petraitiene, 2004, Efficacy, safety and plasma pharmacokinetics of escalating dosages of intravenously administered ravuconazole lysine phosphoester for treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits, Antimicrob Agents Chemother, 48, 1188, 10.1128/AAC.48.4.1188-1196.2004 Pfaller, 2004, In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agents, Diagn Microbiol Infect Dis, 48, 101, 10.1016/j.diagmicrobio.2003.09.009 Pfaller, 2002, Antimicrob Agents Chemother, 46, 1032, 10.1128/AAC.46.4.1032-1037.2002 Pfaller, 2002, In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp, Antimicrob Agents Chemother, 46, 1723, 10.1128/AAC.46.6.1723-1727.2002 Ryley, 1986, Quantification of vaginal Candida albicans infections in rodents, J Med Vet Mycol, 24, 455, 10.1080/02681218680000721 Slavin, 1992, Single dose oral fluconazole vs intravaginal terconazole in treatment of Candida vaginitis. Comparation and pilot study, J Fla Med Assoc, 79, 693 Sobel, 1993, Genital candidiasis, 225 Tooley, 1989, Treatment of vaginal candidosis a UK patient survey, Br J Clin Pract, 71, S73 Yamazumi, 2000, In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans, Antimicrob Agents Chemother, 44, 2883, 10.1128/AAC.44.10.2883-2886.2000